Metformin modulates autophagic pathway in renal fibrosis induced by carbon tetrachloride in adult male albino rats
CONCLUSION: Metformin administration can modulate histological and biochemical effects in the renal tissue induced by of ccl4.PMID:38654519 | DOI:10.1080/01913123.2024.2342444 (Source: Ultrastructural Pathology)
Source: Ultrastructural Pathology - April 24, 2024 Category: Pathology Authors: Amal T Abou-Elghait Rania M Al Adly Eman Radwan Fatma Y Meligy Source Type: research
The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial —Study Design and Protocol
AbstractIntroductionMultiple daily injection insulin regimen (MDI) represents the most intensive insulin regimen used in the management of people with type 2 diabetes (PwT2D). Its efficacy regarding glycaemic control is counterbalanced by the increased risk of hypoglycaemia, frequently observed tendency to weight gain and necessity for frequent glucose monitoring. Recent introduction of novel antidiabetic medications with pleiotropic effects reaching far beyond the reduction of glycaemia (HbA1c), such as the glucagon-like peptide 1 receptor agonist (GLP-1 RA), has significantly widened the therapeutic options available for...
Source: Diabetes Therapy - April 24, 2024 Category: Endocrinology Source Type: research
Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
Dipeptidyl peptidase 4 inhibitors vs. metformin for new-onset dementia: a propensity score-matched cohort study
CONCLUSION: In this real-world study, we found that DPP4 inhibitors presented an association with a lower risk of dementia in individuals with type 2 diabetes than metformin, particularly in older people and those without diabetes-related comorbidities.PMID:38652239 | DOI:10.1210/clinem/dgae281 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 23, 2024 Category: Endocrinology Authors: Siyang Liu Heng Wan Sheng Nie Huanyi Cao Lan Liu Hua Liang Hong Xu Bicheng Liu Chunbo Chen Huafeng Liu Qiongqiong Yang Hua Li Yaozhong Kong Guisen Li Qijun Wan Yan Zha Ying Hu Gang Xu Yongjun Shi Yilun Zhou Guobin Su Ying Tang Mengchun Gong Aixin Guo Jian Source Type: research
Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
Dipeptidyl peptidase 4 inhibitors vs. metformin for new-onset dementia: a propensity score-matched cohort study
CONCLUSION: In this real-world study, we found that DPP4 inhibitors presented an association with a lower risk of dementia in individuals with type 2 diabetes than metformin, particularly in older people and those without diabetes-related comorbidities.PMID:38652239 | DOI:10.1210/clinem/dgae281 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 23, 2024 Category: Endocrinology Authors: Siyang Liu Heng Wan Sheng Nie Huanyi Cao Lan Liu Hua Liang Hong Xu Bicheng Liu Chunbo Chen Huafeng Liu Qiongqiong Yang Hua Li Yaozhong Kong Guisen Li Qijun Wan Yan Zha Ying Hu Gang Xu Yongjun Shi Yilun Zhou Guobin Su Ying Tang Mengchun Gong Aixin Guo Jian Source Type: research
Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy
Am Fam Physician. 2024 Apr;109(4):333-342.ABSTRACTType 2 diabetes mellitus is a chronic disease that is increasing in global prevalence. An individualized approach to pharmacotherapy should consider costs, benefits beyond glucose control, and adverse events. Metformin is the first-line therapy due to its low cost and effectiveness. Sulfonylureas and thiazolidinediones are additional low-cost oral hypoglycemic classes available in the United States; however, evidence shows variability in weight gain and hypoglycemia. Thiazolidinediones increase fluid retention and are not recommended in patients with New York Heart Associat...
Source: American Family Physician - April 22, 2024 Category: Primary Care Authors: Elizabeth M Vaughan Zuleica M Santiago-Delgado Source Type: research
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy
Am Fam Physician. 2024 Apr;109(4):333-342.ABSTRACTType 2 diabetes mellitus is a chronic disease that is increasing in global prevalence. An individualized approach to pharmacotherapy should consider costs, benefits beyond glucose control, and adverse events. Metformin is the first-line therapy due to its low cost and effectiveness. Sulfonylureas and thiazolidinediones are additional low-cost oral hypoglycemic classes available in the United States; however, evidence shows variability in weight gain and hypoglycemia. Thiazolidinediones increase fluid retention and are not recommended in patients with New York Heart Associat...
Source: American Family Physician - April 22, 2024 Category: Primary Care Authors: Elizabeth M Vaughan Zuleica M Santiago-Delgado Source Type: research
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy
Am Fam Physician. 2024 Apr;109(4):333-342.ABSTRACTType 2 diabetes mellitus is a chronic disease that is increasing in global prevalence. An individualized approach to pharmacotherapy should consider costs, benefits beyond glucose control, and adverse events. Metformin is the first-line therapy due to its low cost and effectiveness. Sulfonylureas and thiazolidinediones are additional low-cost oral hypoglycemic classes available in the United States; however, evidence shows variability in weight gain and hypoglycemia. Thiazolidinediones increase fluid retention and are not recommended in patients with New York Heart Associat...
Source: American Family Physician - April 22, 2024 Category: Primary Care Authors: Elizabeth M Vaughan Zuleica M Santiago-Delgado Source Type: research
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy
Am Fam Physician. 2024 Apr;109(4):333-342.ABSTRACTType 2 diabetes mellitus is a chronic disease that is increasing in global prevalence. An individualized approach to pharmacotherapy should consider costs, benefits beyond glucose control, and adverse events. Metformin is the first-line therapy due to its low cost and effectiveness. Sulfonylureas and thiazolidinediones are additional low-cost oral hypoglycemic classes available in the United States; however, evidence shows variability in weight gain and hypoglycemia. Thiazolidinediones increase fluid retention and are not recommended in patients with New York Heart Associat...
Source: American Family Physician - April 22, 2024 Category: Primary Care Authors: Elizabeth M Vaughan Zuleica M Santiago-Delgado Source Type: research
